Ann: Preliminary Final Report, page-4

Transformational Progress and Strategic US Commercialisation Focus
Adherium has significantly advanced its commercial strategy by concentrating on scalable partnerships and
customer relationships, aiming to achieve cash flow positivity by growing its remote patient monitoring
services in the United States.
But........
Sales down by 75% and costs up.

With sales down 75% due to no no clinical trials 1) demonstrates ADRs continues reliance on AZ 2)what the heck are the "strategic partners" doing ? Have Trudell/Monagahan Medical ( announced US distribution partner) given up completely on ADR ?

Strategic Partnerships and Major Milestones
• Allergy Partners: Milestone - None, no commercial report
• SENTA Partners: Milestone - a continued roll out, no commercial report..
• Intermountain Health: Milestone - Our first patient enrolled in February. Its now almost Sept. How many patients ? - no commercial report.
• NuvoAir Medical: Milestone - a minimum purchase of 1,000 Hailie® sensors, Over what period and how many YTD ? - no commercial report.
• Valued Relationships Inc. Milestone - collaboration will enhance our capabilities - So what ? - no commercial report.
• Rimidi: Milestone New partnership April 2024 - its almost Sept. How may patients/sales - no commercial report.

CEO, not sure what you are doing or waiting for. This is not big Pharma where you never run out of money. No one is going to swoop in and save you. ADR was a disruptive technology 20 years ago not now. If the video you posted was supposed to build confidence along with this 4E then it did not do it for me. Nothing new, rehash of the old presented as something new from you. Disingenious to all those who have tried before you without success.
Why this appears to be a no-market when every indicator says it should be huge is frustratng and confusing. It appears to have everything going for it, however no one has cracked it in 20 years. Nothing I have heard in the last 6 months from the current CEO is different to give any confidence ADR will succeed. May be its time for BioScience Managers to bite the bullet. kill it or take it private. That will be painful for all but better than bleeding to death and save us suckers from losing more money cause we are addicted to the hope ADR will succeed and can't turn the life support machine off.